Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature

J Neuroimmunol. 2021 Oct 15;359:577691. doi: 10.1016/j.jneuroim.2021.577691. Epub 2021 Aug 8.


Massive vaccination against COVID-19 has become a global priority. Simultaneously, concerns regarding the safety of vaccines are growing. We describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine. We also summarize 12 published cases of GBS after ChAdOx1 vaccination, highlighting their unique clinical and paraclinical features. We propose a possible association between the risk of GBS and the ChAdOx1 vaccine and recommend surveillance for GBS following vaccination. Population-based studies are needed to determine causality and whether specific subpopulations are susceptible.

Keywords: COVID-19; ChAdOx1; Guillain-Barre syndrome; SARS-CoV-2; Vaccines.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / adverse effects*
  • ChAdOx1 nCoV-19
  • Female
  • Guillain-Barre Syndrome / chemically induced*
  • Guillain-Barre Syndrome / diagnostic imaging*
  • Humans
  • Male
  • Middle Aged


  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19